Aspen strikes deal with J&J to launch own vaccine, called 'Aspenovax'

accreditation
Aspen’s flagship manufacturing site in Gqebhera, Eastern Cape.
Aspen’s flagship manufacturing site in Gqebhera, Eastern Cape.
Photo: Aspen

Aspen will manufacture and sell its own branded Covid-19 vaccine in Africa, following an agreement with Johnson & Johnson.

Johnson & Johnson is granting Aspen an intellectual property licence to produce its vaccine under the new brand name "Aspenovax".

According to the deal, Aspen will manufacture the vaccine from drug substance supplied by Johnson & Johnson, and then sell the vaccine under Aspen branding to African governments.

The agreement runs until end-2026, and can include new versions of the Johnson & Johnson vaccine. These can include boosters or jabs created for new variants.

Aspen, the biggest medicine producer on the continent, currently has an agreement with Johnson & Johnson to package and fill vials of the American company’s vaccine at a plant in Gqeberha.

Aspen's share price has rallied by more than 11% over the past two days. 


        

    
We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Rand - Dollar
15.44
-0.7%
Rand - Pound
20.65
+0.0%
Rand - Euro
17.21
+0.2%
Rand - Aus dollar
10.88
+0.3%
Rand - Yen
0.13
+0.1%
Gold
1,792.49
-1.5%
Silver
22.69
-3.5%
Palladium
2,357.50
+1.0%
Platinum
1,023.00
-1.1%
Brent Crude
89.96
+2.0%
Top 40
67,070
-0.4%
All Share
73,504
-0.4%
Resource 10
75,094
-0.2%
Industrial 25
90,477
-1.1%
Financial 15
15,064
+0.9%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot